Evidence map›Paper›PMID 42897384›Full record

ArticleEuropean journal of pediatrics2026

Impact of

Amirali Kalantari, Maryam Behfar, Zahra Karimizadeh, Atieh Karimzadeh, Zeinab Paymani, Saeed Farzanehfar, Mehrshad Abbasi, Arghavan Tajalli, Sarina Ansari, Pooya Ashkevari and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amirali KalantariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Maryam BehfarPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zahra KarimizadehPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Atieh KarimzadehPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zeinab PaymaniNuclear Medicine Department, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Saeed FarzanehfarDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mehrshad AbbasiDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Arghavan TajalliPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sarina AnsariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pooya AshkevariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Rashin MohseniPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Najibe KaramiPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amir Ali HamidiehPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran. aahamidieh@tums.ac.ir.ORCID http://orcid.org/0000-0002-8935-079X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate whether dose escalation of

conclusionIn this retrospective cohort, escalation from 12 to 18 mCi/kg was associated with faster neutrophil engraftment and a higher rate of normal MIBG scans at 1 year, without a significant difference in OS or EFS. The study was underpowered, and did not demonstrate a significant benefit of either the lower or the higher dose; the optimal dose remains undetermined and requires prospective evaluation. WHAT IS KNOWN: • WHAT IS NEW: • In this direct retrospective comparison (12 vs. 18 mCi/kg), the higher dose was associated with faster neutrophil engraftment and a higher platelet engraftment rate and a higher rate of normal MIBG scans at year, but without a significant difference in OS or EFS, and with a non-significant trend toward more renal and thyroid toxicity. The study was underpowered and did not demonstrate a significant benefit of either dose; the optimal MIBG dose remains undetermined.

Indexed as

3-IodobenzylguanidineHematopoietic Stem Cell TransplantationIodine RadioisotopesNeuroblastomaRadiopharmaceuticalsTransplantation ConditioningAdolescentChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesTransplantation, AutologousTreatment Outcome3-IodobenzylguanidineIodine RadioisotopesRadiopharmaceuticals131I-Meta-iodobenzylguanidineHematopoietic stem cell transplantationNeuroblastoma

Identifiers

PMID42897384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.